Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer’s Xalkori extends lung cancer survival in phase III trial

Pfizer’s Xalkori extends lung cancer survival in phase III trial

26th March 2014

Pfizer has announced its Xalkori treatment has delayed the progression of lung cancer when compared to chemotherapy in a late-stage phase III study.

The medicine was approved in 2011 by the US Food and Drug Administration for use with patients who have a specific gene mutation, but a previous clinical trial showed the drug significantly delayed progression of the disease among those who have undergone chemotherapy for non-small-cell lung cancers (NSCLC), which are the most common form.

Xalkori was originally approved for patients with a gene called ALK, but this mutation occurs in only a small percentage of those diagnosed with lung cancer.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs and chief medical office at Pfizer Oncology, said: "The results of the [study] are important in that they demonstrate, for the first time, that Xalkori is superior to standard chemotherapy doublet regimens in prolonging survival without progression as first-line treatment for patients with ALK-positive advanced NSCLC."

The drug – which is also known under its chemical name crizotinib – recorded global sales of $89 million (53.8 million pounds) in the fourth quarter of 2013.ADNFCR-8000103-ID-801706668-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.